| 10/16/2017 | CV | Market Commentary: Morning Commentary: Isis Pharmaceuticals notches another outright gain
|
| 7/6/2015 | CV | Market Commentary: Convertibles weaker in thin trading; energy issues indicated lower; Qihoo edges downward
|
| 6/30/2015 | CV | Market Commentary: Convertibles lower with month-end in focus; Impax slips below par; June primary falters
|
| 6/30/2015 | CV | Market Commentary: Morning Commentary: Convertibles lower again with month-end in focus; Isis Pharmaceuticals lower
|
| 5/4/2015 | CV | Market Commentary: New Source launches; Isis adds on swap; Ares Capital steady to mixed after earnings miss
|
| 4/9/2015 | CV | Market Commentary: Qihoo, other Asian internet names up again in active trade; Isis improves; Teva at parity
|
| 3/27/2015 | CV | Market Commentary: BioMarin As gain on swap, BioMarin Bs in line amid takeout rumors; health care better bid
|
| 2/3/2015 | CV | Market Commentary: Isis adds on hedge after drug data disappoints; LinkedIn adds outright, on hedge
|
| 2/3/2015 | CV | Market Commentary: Morning Commentary: LinkedIn adds outright, on hedge; Isis Pharmaceuticals lower outright
|
| 1/5/2015 | CV | Market Commentary: Convertibles steady as equities sell off; volumes still low; Isis adds with stock on J&J deal
|
| 1/5/2015 | CV | Market Commentary: Morning Commentary: Isis trades up in line with shares on J&J deal; oil drags markets lower
|
| 12/31/2014 | CV | Market Commentary: Outlook 2015: U.S. convertibles primary notches multi-year high; volume expected to climb
|
| 12/16/2014 | CV | Market Commentary: Convertibles weaken further amid market turmoil; Lukoil drops; technology names lower
|
| 12/16/2014 | CV | Market Commentary: Morning Commentary: Convertibles weaken further amid market turmoil; Lukoil drops
|
| 12/15/2014 | CV | Market Commentary: American Realty lower; Isis Pharmaceuticals paper drops outright, ‘comes in’ on hedge
|
| 11/21/2014 | CV | Isis greenshoe exercise lifts 1% seven-year convertibles $425 million
|
| 11/12/2014 | CV | Market Commentary: New Isis Pharmaceuticals trades below par, slips on hedge; Dendreon steady; Home Inns adds
|
| 11/12/2014 | CV | Market Commentary: Morning Commentary: New Isis trades below par, slips on hedge; Dendreon trading at 55.5
|
| 11/12/2014 | CV | New Issue: Isis Pharmaceuticals prices $425 million seven-year convertibles to yield 1%, up 30%
|
| 11/11/2014 | CV | Market Commentary: Existing Isis bonds, shares up; planned Isis looks slightly rich; Ascent Capital shares drop
|
| 11/11/2014 | CV | Market Commentary: Morning Commentary: Planned Isis looks slightly rich, shares jump; Ascent Capital shares drop
|
| 11/10/2014 | CV | Market Commentary: Dendreon drops after bankruptcy filing; Salix recoups some; Isis Pharmaceuticals on tap
|
| 11/10/2014 | CV | Isis Pharmaceuticals to price $425 million seven-year convertibles to yield 0.5%-1%, up 30%-35%
|
| 8/26/2014 | CV | Market Commentary: Priceline, Illumina trade in line; Medivation, Isis in focus; Prospect Capital bid lower
|
| 12/31/2013 | CV | Outlook 2014: U.S. secondary market poised for continued strength, but investors eye Fed taper
|
| 9/23/2013 | CV | Market Commentary: Convertibles mostly in line with lower shares; gold names in focus; Isis edges up on hedge
|
| 9/13/2012 | CVLM | Isis Pharmaceuticals redeems all $162.5 million convertibles due 2027
|
| 8/13/2012 | CVLM | Isis Pharmaceuticals calls $162.5 million all convertibles due 2027
|
| 8/10/2012 | CV | Market Commentary: MGM better on outright demand; Janus adds on investment stake; Hornbeck trades up, in line
|
| 8/9/2012 | CV | Market Commentary: New Exelixis gains on debut; new Prospect Capital prices at a discount; Medicis better
|
| 8/8/2012 | CV | Market Commentary: Isis pops on debut; older paper slips again; new Hornbeck adds; Tyson comes 'in' slightly
|
| 8/8/2012 | CV | New Issue: Isis Pharmaceuticals sells $201.25 million seven-year convertibles at 2.75%, up 32.5%
|
| 8/7/2012 | CV | Isis Pharmaceuticals revises talk on $175 million seven-year convertibles to 2.75%, up 32.5%
|
| 8/7/2012 | CV | Market Commentary: Existing Isis drops amid new deal, call; planned Isis price talk revised; Kodak falls
|
| 8/6/2012 | CV | Isis Pharmaceuticals offers $175 million seven-year convertibles at 3%-3.5%, up 27.5%-32.5%
|
| 8/6/2012 | CV | Market Commentary: Knight extends strong gains on capital infusion; Isis moves up with shares, launches deal
|
| 8/6/2012 | CVLM | Isis Pharma may buy back 2.625% convertibles using offer proceeds
|
| 7/9/2012 | CV | Market Commentary: Central European jumps 8-9 points outright; Molina Healthcare comes in 2 points on hedge
|
| 7/5/2012 | CV | Market Commentary: Convertibles market quiet; Navistar steady before conference call; Patriot Coal around 30
|
| 6/27/2012 | CV | Market Commentary: High-grade names in focus; Lennar adds; Isis under pressure; Gevo to price $30 million
|
| 5/21/2012 | CV | Market Commentary: Kodak collapses on patent ruling; lesser credits weak; Newmont expands; SanDisk active
|
| 3/1/2010 | CV | Market Commentary: Millipore a little weaker dollar neutral, but OSI Pharma expands; Amylin, Isis also in trade
|
| 1/8/2008 | CV | Market Commentary: Countrywide bashed on bankruptcy rumors, financials suffer; UAL, AMR, airlines squashed; ISIS surges
|
| 10/10/2007 | CV | Market Commentary: Molson Coors continues hot streak; Countrywide edges up; ISIS, Level 3 fall; Rayonier, iStar set to play
|
| 4/12/2007 | CV | Isis Pharmaceuticals calls all of 51/2% convertibles due 2009
|
| 1/24/2007 | CV | Isis greenshoe fully exercised, upping convertibles to $142.5 million
|
| 1/18/2007 | CV | Market Commentary: Lehman ends commissions for clients; Isis jumps on debut; National Financial makes quiet start
|
| 1/18/2007 | CV | New Issue: Isis prices $125 million 20-year convertibles within talk, at 2.625%, up 30%
|
| 1/17/2007 | CV | Market Commentary: Headwaters rises at start; Vornado flat on rumors; Washington quiet; Isis, National Financial reviews differ
|
| 1/16/2007 | CV | Isis to price $125 million 20-year convertibles Wednesday, talked at 2.5%-3%, up 27.5%-32.5%
|
| 1/16/2007 | CV | Market Commentary: Genesis soars on buyout; Symantec falls outright on warning; Headwaters strong in gray; issuance picks up
|
| 1/16/2007 | CV | Isis Pharmaceuticals plans to redeem remaining 5.5% convertibles
|
| 2/8/2006 | CV | Market Commentary: Citadel retraces some gains; Qwest flat but adds on hedge; MGI better; Oil States lower; Pier 1 prices
|
| 2/1/2006 | CV | Market Commentary: JetBlue, Pixelworks down on earnings, but Cymer up; Schlumberger drops
|
| 7/15/2005 | CV | Market Commentary: Chiron drops as convertibles market trades mostly flat to lower; but CV Therapeutics, Isis gain
|
| 1/12/2005 | CV | Market Commentary: Level 3 higher on job cuts; CenturyTel off; Kodak up; Advanced Micro rebounds
|
| 3/17/2003 | CV | Market Commentary: Markets go green on war visibility; spate of deals hold promise for busy week
|
| 6/12/2002 | CV | Deutsche on biopharma: buy Inhale, Cell Therapeutics; hold Abgenix, Alexion; sell Vertex, ISIS
|
| 5/17/2002 | CV | Market Commentary: LifePoint gains in hungry market; El Paso drops on "bad" news
|
| 4/26/2002 | CV | New Issue: Isis Pharma $125 million convertibles at 5.5% yield, up 25%
|
| 4/26/2002 | CV | Market Commentary: New issues lower with broader market; Alltel launches $1.25 billion
|
| 4/25/2002 | CV | Market Commentary: Market declines on earnings, events; new issues trickle in
|
| 4/24/2002 | CV | Market Commentary: Calpine, Tyco active on fresh round of news, Waste Connections sells floater
|
| 4/24/2002 | CV | Isis Pharmaceuticals to use $74 million of convertibles proceeds to retire 14% notes
|
| 4/23/2002 | CV | ISIS Pharmaceuticals $125 million convertibles talked at 5.0-5.5% yield, up 20-25%
|
| 4/23/2002 | CV | Market Commentary: New issues invigorate otherwise languid market; Calpine seen heading south
|
